Verana Health acquired oncology‑focused RWD provider COTA Healthcare for $52 million, merging complementary specialty datasets and analytics to serve more therapeutic areas. The combined company claims coverage of over 95 million patients and relationships with 17 of the top 20 global pharma firms. Verana CEO Sujay Jadhav framed the deal as expanding therapeutic expertise from ophthalmology and urology into oncology while improving curation, validation and clinical annotation. COTA’s oncology curation and clinician network are expected to accelerate Verana’s ability to generate regulatory‑grade real‑world evidence for trials and post‑market studies. The acquisition underscores continued consolidation in the RWD/RWE market as pharma customers demand higher‑quality, curated data for label expansions, MRD validation, and safety evidence generation.